ReShape Lifesciences (RSLS) Competitors $2.83 +0.15 (+5.60%) Closing price 04:00 PM EasternExtended Trading$2.84 +0.00 (+0.18%) As of 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock RSLS vs. BIAF, ABT, ISRG, BSX, SYK, MDT, BDX, EW, IDXX, and RMDShould you be buying ReShape Lifesciences stock or one of its competitors? The main competitors of ReShape Lifesciences include bioAffinity Technologies (BIAF), Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Boston Scientific (BSX), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), and ResMed (RMD). These companies are all part of the "medical" sector. ReShape Lifesciences vs. Its Competitors bioAffinity Technologies Abbott Laboratories Intuitive Surgical Boston Scientific Stryker Medtronic Becton, Dickinson and Company Edwards Lifesciences IDEXX Laboratories ResMed bioAffinity Technologies (NASDAQ:BIAF) and ReShape Lifesciences (NASDAQ:RSLS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership. Is BIAF or RSLS more profitable? ReShape Lifesciences has a net margin of -48.26% compared to bioAffinity Technologies' net margin of -110.53%. ReShape Lifesciences' return on equity of -251.90% beat bioAffinity Technologies' return on equity.Company Net Margins Return on Equity Return on Assets bioAffinity Technologies-110.53% -367.64% -154.15% ReShape Lifesciences -48.26%-251.90%-59.49% Which has more risk & volatility, BIAF or RSLS? bioAffinity Technologies has a beta of 2.52, suggesting that its share price is 152% more volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Do analysts prefer BIAF or RSLS? bioAffinity Technologies presently has a consensus target price of $6.00, suggesting a potential upside of 1,718.18%. Given bioAffinity Technologies' higher possible upside, equities research analysts clearly believe bioAffinity Technologies is more favorable than ReShape Lifesciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bioAffinity Technologies 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00ReShape Lifesciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has better earnings and valuation, BIAF or RSLS? ReShape Lifesciences has lower revenue, but higher earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than ReShape Lifesciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatiobioAffinity Technologies$9.36M1.00-$9.04M-$0.72-0.46ReShape Lifesciences$8.01M0.84-$7.13M-$193.23-0.01 Does the media favor BIAF or RSLS? In the previous week, bioAffinity Technologies had 1 more articles in the media than ReShape Lifesciences. MarketBeat recorded 2 mentions for bioAffinity Technologies and 1 mentions for ReShape Lifesciences. ReShape Lifesciences' average media sentiment score of 1.87 beat bioAffinity Technologies' score of 0.19 indicating that ReShape Lifesciences is being referred to more favorably in the news media. Company Overall Sentiment bioAffinity Technologies Neutral ReShape Lifesciences Very Positive Do insiders and institutionals hold more shares of BIAF or RSLS? 1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 22.1% of ReShape Lifesciences shares are held by institutional investors. 16.9% of bioAffinity Technologies shares are held by company insiders. Comparatively, 0.0% of ReShape Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummarybioAffinity Technologies and ReShape Lifesciences tied by winning 7 of the 14 factors compared between the two stocks. Get ReShape Lifesciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RSLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RSLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RSLS vs. The Competition Export to ExcelMetricReShape LifesciencesMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.76M$6.67B$5.57B$9.31BDividend YieldN/A1.20%4.23%4.03%P/E Ratio-0.0125.4928.6119.73Price / Sales0.8487.71411.31174.27Price / CashN/A20.3636.0257.96Price / Book-0.334.668.235.67Net Income-$7.13M$174.76M$3.23B$257.79M7 Day Performance13.20%-1.13%-0.01%0.52%1 Month Performance-1.39%1.22%5.60%8.84%1 Year Performance-99.17%2.58%26.54%14.18% ReShape Lifesciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RSLSReShape Lifesciences0.614 of 5 stars$2.83+5.6%N/A-99.2%$6.76M$8.01M-0.0150BIAFbioAffinity Technologies1.3689 of 5 stars$0.29-6.5%$6.00+1,992.1%-88.4%$8.16M$8.81M-0.4010News CoverageABTAbbott Laboratories4.9438 of 5 stars$132.05+0.0%$143.11+8.4%+27.6%$229.74B$42.34B17.13114,000Trending NewsUpcoming EarningsAnalyst ForecastISRGIntuitive Surgical4.7095 of 5 stars$516.44+0.9%$592.86+14.8%+17.1%$185.10B$8.35B75.7215,638Positive NewsUpcoming EarningsAnalyst ForecastAnalyst RevisionBSXBoston Scientific4.6114 of 5 stars$104.39+1.1%$116.09+11.2%+32.6%$154.43B$16.75B76.1953,000Upcoming EarningsSYKStryker4.4439 of 5 stars$391.46+0.5%$428.55+9.5%+18.9%$149.41B$22.60B52.9053,000Positive NewsAnalyst ForecastMDTMedtronic4.6196 of 5 stars$89.73-0.2%$97.47+8.6%+15.7%$115.08B$33.54B24.7995,000Positive NewsAnalyst ForecastAnalyst RevisionBDXBecton, Dickinson and Company4.8174 of 5 stars$177.15+0.7%$219.22+23.7%-21.1%$50.77B$20.87B33.8174,000Positive NewsAnalyst RevisionHigh Trading VolumeEWEdwards Lifesciences4.353 of 5 stars$78.35+0.4%$80.40+2.6%-14.1%$45.96B$5.44B11.1915,800Positive NewsUpcoming EarningsAnalyst ForecastIDXXIDEXX Laboratories3.6435 of 5 stars$531.42-0.4%$558.11+5.0%+9.1%$42.74B$3.93B49.1111,000Positive NewsRMDResMed4.4197 of 5 stars$254.09-0.1%$259.33+2.1%+22.7%$37.26B$5.02B28.529,980News CoveragePositive NewsAnalyst UpgradeAnalyst Revision Related Companies and Tools Related Companies BIAF Alternatives ABT Alternatives ISRG Alternatives BSX Alternatives SYK Alternatives MDT Alternatives BDX Alternatives EW Alternatives IDXX Alternatives RMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RSLS) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ReShape Lifesciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ReShape Lifesciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
